Roy Buchanan
Stock Analyst at JMP Securities
(0.82)
# 3,540
Out of 4,827 analysts
59
Total ratings
27.27%
Success rate
-24.25%
Average return
Main Sectors:
Stocks Rated by Roy Buchanan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DVAX Dynavax Technologies | Maintains: Market Outperform | $33 → $31 | $9.66 | +220.91% | 6 | May 7, 2025 | |
| ANTX AN2 Therapeutics | Maintains: Market Outperform | $5 → $2 | $1.17 | +70.94% | 9 | May 5, 2025 | |
| CDTX Cidara Therapeutics | Reiterates: Market Outperform | $46 | $18.75 | +145.33% | 2 | Apr 29, 2025 | |
| INO Inovio Pharmaceuticals | Reiterates: Market Outperform | $18 | $1.82 | +889.01% | 3 | Mar 14, 2025 | |
| CVAC CureVac | Reiterates: Market Outperform | $16 | $3.52 | +354.55% | 8 | Feb 14, 2025 | |
| TPG TPG Inc. | Reiterates: Market Perform | n/a | $49.21 | - | 1 | Feb 13, 2025 | |
| ESPR Esperion Therapeutics | Reiterates: Market Outperform | $7 → $4 | $0.86 | +365.39% | 3 | Feb 11, 2025 | |
| ENTA Enanta Pharmaceuticals | Reiterates: Market Outperform | $21 | $5.40 | +288.89% | 12 | Feb 11, 2025 | |
| IRWD Ironwood Pharmaceuticals | Maintains: Market Outperform | $23 → $14 | $0.72 | +1,842.29% | 1 | Jan 30, 2025 | |
| ABVX ABIVAX Société Anonyme | Reiterates: Market Outperform | $33 | $6.92 | +377.22% | 1 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $24 → $7 | $1.45 | +382.76% | 2 | Nov 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $4 → $5 | $3.33 | +50.38% | 5 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $443 → $448 | $563.17 | -20.45% | 2 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $14 → $16 | $12.20 | +31.15% | 1 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.84 | - | 2 | Feb 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $420 | $2.79 | +14,930.06% | 1 | Sep 14, 2021 |
Dynavax Technologies
May 7, 2025
Maintains: Market Outperform
Price Target: $33 → $31
Current: $9.66
Upside: +220.91%
AN2 Therapeutics
May 5, 2025
Maintains: Market Outperform
Price Target: $5 → $2
Current: $1.17
Upside: +70.94%
Cidara Therapeutics
Apr 29, 2025
Reiterates: Market Outperform
Price Target: $46
Current: $18.75
Upside: +145.33%
Inovio Pharmaceuticals
Mar 14, 2025
Reiterates: Market Outperform
Price Target: $18
Current: $1.82
Upside: +889.01%
CureVac
Feb 14, 2025
Reiterates: Market Outperform
Price Target: $16
Current: $3.52
Upside: +354.55%
TPG Inc.
Feb 13, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $49.21
Upside: -
Esperion Therapeutics
Feb 11, 2025
Reiterates: Market Outperform
Price Target: $7 → $4
Current: $0.86
Upside: +365.39%
Enanta Pharmaceuticals
Feb 11, 2025
Reiterates: Market Outperform
Price Target: $21
Current: $5.40
Upside: +288.89%
Ironwood Pharmaceuticals
Jan 30, 2025
Maintains: Market Outperform
Price Target: $23 → $14
Current: $0.72
Upside: +1,842.29%
ABIVAX Société Anonyme
Jan 10, 2025
Reiterates: Market Outperform
Price Target: $33
Current: $6.92
Upside: +377.22%
Nov 21, 2024
Maintains: Market Outperform
Price Target: $24 → $7
Current: $1.45
Upside: +382.76%
Aug 2, 2024
Maintains: Market Outperform
Price Target: $4 → $5
Current: $3.33
Upside: +50.38%
Mar 3, 2023
Maintains: Market Outperform
Price Target: $443 → $448
Current: $563.17
Upside: -20.45%
Mar 1, 2023
Maintains: Market Perform
Price Target: $14 → $16
Current: $12.20
Upside: +31.15%
Feb 16, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $0.84
Upside: -
Sep 14, 2021
Initiates: Market Outperform
Price Target: $420
Current: $2.79
Upside: +14,930.06%